vs
Side-by-side financial comparison of Alkermes plc. (ALKS) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $384.5M, roughly 1.6× Alkermes plc.). Royalty Pharma plc runs the higher net margin — 34.4% vs 12.8%, a 21.6% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -10.6%). Over the past eight quarters, Alkermes plc.'s revenue compounded faster (4.8% CAGR vs 4.6%).
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
ALKS vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $384.5M | $622.0M |
| Net Profit | $49.3M | $214.2M |
| Gross Margin | 88.0% | — |
| Operating Margin | 15.1% | 62.4% |
| Net Margin | 12.8% | 34.4% |
| Revenue YoY | -10.6% | 4.8% |
| Net Profit YoY | -66.3% | 2.9% |
| EPS (diluted) | $0.29 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $384.5M | $622.0M | ||
| Q3 25 | $394.2M | $609.3M | ||
| Q2 25 | $390.7M | $578.7M | ||
| Q1 25 | $306.5M | $568.2M | ||
| Q4 24 | $430.0M | $593.6M | ||
| Q3 24 | $378.1M | $564.7M | ||
| Q2 24 | $399.1M | $537.3M | ||
| Q1 24 | $350.4M | $568.0M |
| Q4 25 | $49.3M | $214.2M | ||
| Q3 25 | $82.8M | $288.2M | ||
| Q2 25 | $87.1M | $30.2M | ||
| Q1 25 | $22.5M | $238.3M | ||
| Q4 24 | $146.5M | $208.2M | ||
| Q3 24 | $92.4M | $544.0M | ||
| Q2 24 | $91.4M | $102.0M | ||
| Q1 24 | $36.8M | $4.8M |
| Q4 25 | 88.0% | — | ||
| Q3 25 | 86.9% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.9% | — | ||
| Q4 24 | 85.6% | — | ||
| Q3 24 | 83.3% | — | ||
| Q2 24 | 84.6% | — | ||
| Q1 24 | 83.3% | — |
| Q4 25 | 15.1% | 62.4% | ||
| Q3 25 | 22.6% | 70.1% | ||
| Q2 25 | 23.8% | 36.3% | ||
| Q1 25 | 4.5% | 94.0% | ||
| Q4 24 | 37.8% | 60.9% | ||
| Q3 24 | 27.7% | — | ||
| Q2 24 | 27.5% | 50.2% | ||
| Q1 24 | 12.4% | -13.0% |
| Q4 25 | 12.8% | 34.4% | ||
| Q3 25 | 21.0% | 47.3% | ||
| Q2 25 | 22.3% | 5.2% | ||
| Q1 25 | 7.3% | 41.9% | ||
| Q4 24 | 34.1% | 35.1% | ||
| Q3 24 | 24.4% | 96.3% | ||
| Q2 24 | 22.9% | 19.0% | ||
| Q1 24 | 10.5% | 0.8% |
| Q4 25 | $0.29 | $0.49 | ||
| Q3 25 | $0.49 | $0.67 | ||
| Q2 25 | $0.52 | $0.07 | ||
| Q1 25 | $0.13 | $0.55 | ||
| Q4 24 | $0.88 | $0.46 | ||
| Q3 24 | $0.55 | $1.21 | ||
| Q2 24 | $0.53 | $0.23 | ||
| Q1 24 | $0.21 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.6M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $1.8B | $9.7B |
| Total Assets | $2.5B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.6M | $618.7M | ||
| Q3 25 | $616.4M | $938.9M | ||
| Q2 25 | $521.2M | $631.9M | ||
| Q1 25 | $399.8M | $1.1B | ||
| Q4 24 | $291.1M | $929.0M | ||
| Q3 24 | $396.3M | $950.1M | ||
| Q2 24 | $535.1M | $1.8B | ||
| Q1 24 | $420.8M | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $1.8B | $9.7B | ||
| Q3 25 | $1.7B | $9.6B | ||
| Q2 25 | $1.6B | $9.5B | ||
| Q1 25 | $1.5B | $9.8B | ||
| Q4 24 | $1.5B | $10.3B | ||
| Q3 24 | $1.3B | $10.3B | ||
| Q2 24 | $1.3B | $9.8B | ||
| Q1 24 | $1.3B | $9.9B |
| Q4 25 | $2.5B | $19.6B | ||
| Q3 25 | $2.3B | $19.3B | ||
| Q2 25 | $2.3B | $18.3B | ||
| Q1 25 | $2.1B | $17.6B | ||
| Q4 24 | $2.1B | $18.2B | ||
| Q3 24 | $2.2B | $18.0B | ||
| Q2 24 | $2.2B | $17.7B | ||
| Q1 24 | $2.1B | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $170.1M | $827.1M |
| Free Cash FlowOCF − Capex | $170.0M | — |
| FCF MarginFCF / Revenue | 44.2% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 3.45× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $480.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $170.1M | $827.1M | ||
| Q3 25 | $101.7M | $702.6M | ||
| Q2 25 | $150.2M | $364.0M | ||
| Q1 25 | $98.8M | $596.1M | ||
| Q4 24 | $190.4M | $742.5M | ||
| Q3 24 | $81.6M | $703.6M | ||
| Q2 24 | $146.0M | $658.2M | ||
| Q1 24 | $21.1M | $664.6M |
| Q4 25 | $170.0M | — | ||
| Q3 25 | $84.4M | — | ||
| Q2 25 | $137.2M | — | ||
| Q1 25 | $88.7M | — | ||
| Q4 24 | $180.6M | — | ||
| Q3 24 | $73.3M | — | ||
| Q2 24 | $138.9M | — | ||
| Q1 24 | $12.8M | — |
| Q4 25 | 44.2% | — | ||
| Q3 25 | 21.4% | — | ||
| Q2 25 | 35.1% | — | ||
| Q1 25 | 28.9% | — | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 3.6% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | 3.45× | 3.86× | ||
| Q3 25 | 1.23× | 2.44× | ||
| Q2 25 | 1.72× | 12.06× | ||
| Q1 25 | 4.40× | 2.50× | ||
| Q4 24 | 1.30× | 3.57× | ||
| Q3 24 | 0.88× | 1.29× | ||
| Q2 24 | 1.60× | 6.45× | ||
| Q1 24 | 0.57× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
